Jilin Provincial Cardiovascular Research Institute, Department of Cardiology in the Third Hospital of Jilin University, Jilin, China.
J Int Med Res. 2021 Nov;49(11):3000605211058875. doi: 10.1177/03000605211058875.
The current therapy for myocarditis is immunosuppressive therapy. However, in rare cases in which patients do not respond to intervention, their condition can rapidly deteriorate to myocarditis with shock, which is characterized by extensive and diffuse lymphocyte infiltration in the myocardium. Most cases of myocarditis are caused by virus-mediated damage of cardiomyocytes, and its clinical manifestations are ventricular arrhythmia and hemodynamic disturbances. Extracorporeal membrane oxygenation is an effective intervention, which regulates hemodynamic stability and avoids systemic hypoperfusion. This intervention has been used to sustain hemodynamic stability in patients with myocarditis and shock. We report here early application of extracorporeal membrane oxygenation for successful treatment of a patient with myocarditis and shock.
目前心肌炎的治疗方法是免疫抑制疗法。然而，在极少数情况下，患者对干预措施没有反应，他们的病情可能会迅速恶化，发展为心肌炎伴休克，其特征是心肌内广泛弥漫的淋巴细胞浸润。大多数心肌炎是由病毒介导的心肌细胞损伤引起的，其临床表现为室性心律失常和血流动力学紊乱。体外膜肺氧合是一种有效的干预措施，可以调节血流动力学稳定性，避免全身低灌注。这种干预措施已被用于维持心肌炎和休克患者的血流动力学稳定。我们在此报告了早期应用体外膜肺氧合成功治疗心肌炎伴休克患者的病例。
